NYSE:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $14.33 +0.18 (+1.27%) Closing price 04:00 PM EasternExtended Trading$14.34 +0.01 (+0.03%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About MBX Biosciences Stock (NYSE:MBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$13.92▼$15.0450-Day Range$9.73▼$15.4952-Week Range$4.81▼$27.50Volume280,074 shsAverage Volume328,877 shsMarket Capitalization$481.40 millionP/E RatioN/ADividend YieldN/APrice Target$37.63Consensus RatingBuy Company Overview MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. Read More MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreMBX MarketRank™: MBX Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 544th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMBX Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MBX Biosciences is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MBX Biosciences is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MBX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MBX. News and Social Media2.9 / 5News Sentiment0.15 News SentimentMBX Biosciences has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MBX Biosciences this week, compared to 2 articles on an average week.Search Interest7 people have searched for MBX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders52.19% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Stock News HeadlinesMBX Biosciences Insiders Added US$579.8k Of Stock To Their HoldingsAugust 20 at 8:26 PM | uk.finance.yahoo.comMBX Biosciences Submits IND for Once-Monthly Obesity DrugAugust 20 at 3:37 AM | finance.yahoo.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.August 22 at 2:00 AM | Porter & Company (Ad)Reviewing MBX Biosciences (MBX) & Its RivalsAugust 20 at 2:11 AM | americanbankingnews.comHead-To-Head Survey: MBX Biosciences (MBX) versus Its CompetitorsAugust 16, 2025 | americanbankingnews.comA Glimpse of MBX Biosciences's Earnings PotentialAugust 14, 2025 | benzinga.comMBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 13, 2025 | americanbankingnews.comMBX Biosciences Reports Progress and Financial StabilityAugust 11, 2025 | tipranks.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $18.43 at the start of the year. Since then, MBX shares have decreased by 22.2% and is now trading at $14.33. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NYSE:MBX) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.72) by $0.06. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $163 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share. Who are MBX Biosciences' major shareholders? Top institutional investors of MBX Biosciences include MPM Bioimpact LLC (3.85%), EcoR1 Capital LLC (3.42%), Franklin Resources Inc. (1.48%) and Geode Capital Management LLC (1.04%). Insiders that own company stock include Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk and Ora H Pescovitz. View institutional ownership trends. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MBX Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings11/07/2024Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:MBX Previous SymbolNYSE:MBX CIK1776111 Webmbxbio.com Phone(317) 659-0200FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Price Target for MBX Biosciences$37.63 High Price Target$44.00 Low Price Target$30.00 Potential Upside/Downside+165.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,594,000Free FloatN/AMarket Cap$475.36 million OptionableN/A BetaN/A Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:MBX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.